{
  "kind": "treatment",
  "slug": "duloxetine-cymbalta",
  "type": "antidepressant",
  "name": "Duloxetine (Cymbalta)",
  "summary": "An SNRI used for depression, anxiety, and certain pain disorders.",
  "description": "Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. It works by inhibiting the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmission in the central nervous system.",
  "category": "medications/antidepressants",
  "tags": [
    "snri",
    "depression",
    "anxiety",
    "neuropathic pain"
  ],
  "metadata": {
    "drug_classes": [
      "SNRI",
      "Antidepressant",
      "Analgesic (neuropathic)"
    ],
    "therapeutic_categories": [
      "Depression",
      "Anxiety",
      "Pain Disorders"
    ],
    "mechanism_categories": [
      "SNRI"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Cymbalta"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Primary Care",
      "Pain Management",
      "Neurology"
    ],
    "fda_approval_year": 2004
  },
  "clinical_metadata": {
    "primary_indications": [
      "Depression",
      "Anxiety",
      "Pain",
      "Other"
    ],
    "off_label_uses": [
      "Stress urinary incontinence",
      "Chemotherapy-induced peripheral neuropathy"
    ],
    "contraindications": [
      "Concurrent use of MAOIs or within 14 days",
      "Uncontrolled narrow-angle glaucoma",
      "Hypersensitivity to duloxetine"
    ],
    "monitoring_required": [
      "Liver function tests",
      "Blood pressure",
      "Mood and suicidality"
    ],
    "efficacy_rating": {
      "depression": 4,
      "anxiety": 4,
      "neuropathic_pain": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "duloxetine",
      "cymbalta",
      "snri",
      "antidepressant",
      "fibromyalgia",
      "neuropathic pain"
    ],
    "synonyms": [
      "duloxetine hydrochloride"
    ],
    "common_misspellings": [
      "duloxitine",
      "cymbolta"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Major Depressive Disorder (MDD)",
        "Generalized Anxiety Disorder (GAD)",
        "Diabetic Peripheral Neuropathic Pain",
        "Fibromyalgia",
        "Chronic Musculoskeletal Pain"
      ]
    },
    {
      "type": "mechanism",
      "text": "Inhibits the reuptake of serotonin and norepinephrine in the CNS, increasing their availability in the synaptic cleft."
    },
    {
      "type": "dosing",
      "adult": {
        "depression_anxiety": "Start 30–60 mg once daily; may increase to 60–120 mg/day",
        "pain_disorders": "Start 30 mg once daily for 1 week, then increase to 60 mg/day"
      },
      "geriatric": "Consider lower initial dose due to increased sensitivity",
      "hepatic_impairment": "Avoid use in chronic liver disease or substantial hepatic impairment",
      "renal_impairment": "Avoid if severe (CrCl < 30 mL/min)"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Delayed-release capsules: 20 mg, 30 mg, 40 mg, 60 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Initial symptom improvement may occur in 1–2 weeks; full effect in 4–6 weeks. Pain relief may be noted within 1 week."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "dry mouth",
        "somnolence",
        "fatigue",
        "constipation",
        "decreased appetite",
        "sweating"
      ],
      "less_common": [
        "dizziness",
        "sexual dysfunction",
        "insomnia",
        "increased blood pressure"
      ],
      "serious": [
        "hepatotoxicity",
        "serotonin syndrome",
        "hyponatremia/SIADH",
        "angle-closure glaucoma"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults.",
      "other": [
        "May cause liver injury—monitor LFTs",
        "Can increase blood pressure—monitor regularly",
        "Risk of serotonin syndrome, especially with other serotonergic agents"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Serotonin syndrome",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Other serotonergic drugs",
          "risk": "Serotonin syndrome",
          "action": "Use caution"
        },
        {
          "with": "Strong CYP1A2 inhibitors (e.g., fluvoxamine)",
          "risk": "Increased duloxetine levels",
          "action": "Avoid or reduce dose"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Mood and suicidality",
        "Blood pressure",
        "Liver function tests",
        "Signs of serotonin syndrome"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; possible neonatal withdrawal if used late in pregnancy",
      "lactation": "Excreted in breast milk; use caution",
      "pediatrics": "Not FDA-approved for pediatric depression or anxiety",
      "geriatrics": "Increased sensitivity to adverse effects"
    },
    {
      "type": "tapering",
      "text": "Gradually decrease dose over 1–2 weeks or longer to minimize withdrawal symptoms such as dizziness, irritability, and paresthesias."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Monitor liver enzymes periodically, especially in patients with alcohol use",
        "Useful for patients with co-occurring depression/anxiety and chronic pain",
        "Avoid abrupt discontinuation due to risk of withdrawal symptoms"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Cymbalta Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "APA Practice Guidelines for Depression",
          "url": "https://www.psychiatry.org/"
        },
        {
          "label": "NICE Guidelines for Neuropathic Pain",
          "url": "https://www.nice.org.uk/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Duloxetine (Cymbalta): Depression, Anxiety & Pain Treatment",
    "description": "Duloxetine (Cymbalta) is an SNRI antidepressant used for depression, anxiety, and certain chronic pain conditions."
  }
}
